Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 827

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 7A
Chunk 827
---
 $811,000
in acquisition costs.

Cash
and Cash Equivalents

For
the purpose of the consolidated statement of cash flows, the Company considers all highly liquid investments with original
maturities of three months or less at the time of purchase to be cash equivalents. Cash equivalents are stated at cost, which
approximates market value because of the short maturity of these instruments.

Concentration
of Risk

The
Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit
of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial
condition, results of operations, and cash flows.

Advertising
Expense

The
Company expenses all advertising costs as incurred. Advertising expenses were approximately $267,201 and $88,832 for the years ended
December 31, 2024 and 2023, respectively.

    F-8

Loss
Per Share

Basic
loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of the Company’s
Common Stock, par value $0.007 per share outstanding during the period. Diluted loss per share is computed by dividing net loss attributable
to common stockholders by the sum of the weighted-average number of shares of Common Stock outstanding during the period and the weighted-average
number of dilutive Common Stock equivalents outstanding during the period, using the treasury stock method. Dilutive Common Stock equivalents
are comprised of in-the-money stock options, convertible notes payable, and warrants based on the average stock price for each period
using the treasury stock method.

The
following potentially dilutive securities have been excluded from the computations of weighted average shares of Common Stock outstanding
as of December 31, 2024 and 2023, as they would be anti-dilutive:

SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES

    As
    of December 31, 

    2024  
    2023 
  
    Shares underlying options outstanding 
     304,125  
     683,695 
  
    Shares underlying warrants outstanding 
     12,298,124  
     — 
  
    Shares underlying unvested
    restricted stock outstanding 
     349,057  
     4,649,952 
  
    Anti-dilutive
    securities 
     12,951,306  
     5